Biogen

News

x-ray image of human head with brain and electric pulses

ICER says lecanemab data in Alzheimer's "inconclusive"

One of the most highly-anticipated developments in pharma next year will be the FDA's verdict on Eisai's accelerated application for lecanemab in Alzheimer's disease, due early in January.<

Digital

Four ways Biogen is tackling digital innovation in neurologi...

Digital transformation in pharma is not a singular endeavour.

News

Eisai's full lecanemab phase 3 trial results for Alzheimer's...

Following the news of two lecanemab-related deaths reported on the eve of the C

R&D

Concept of memory loss and brain aging due to dementia and alzheimer's disease as a medical icon with fall trees shaped as a human head losing leaves with 3D illustration elements.

Two drug-related deaths reported on eve of Phase 3 lecanemab...

It continues to be a rocky road for amyloid-targeting drugs for Alzheimer's disease.

News

Illustration of a nerve cell on a colored background with light effects

Alzheimer's treatment hopes take another dive as Roche drug ...

Roche's Genentech division has reported disappointing top-line results from its highly-anticipated phase 3 trial of gantenerumab in early Alzheimer's disease, in yet another setback for an

News